Results 71 to 80 of about 39,319 (333)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK

eJHaem, 2021
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis   +6 more
doaj   +1 more source

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK

Frontiers in Immunology, 2023
IntroductionCytotoxic CD8+ T cell (CTL) exhaustion is a dysfunctional state of T cells triggered by persistent antigen stimulation, with the characteristics of increased inhibitory receptors, impaired cytokine production and a distinct transcriptional ...
Ling Li, Manzhi Zhao, Caoimhe H. Kiernan, Melisa D. Castro Eiro, Marjan van Meurs, Inge Brouwers-Haspels, Merel E. P. Wilmsen, Dwin G. B. Grashof, Harmen J. G. van de Werken, Harmen J. G. van de Werken, Rudi W. Hendriks, Yvonne M. Mueller, Peter D. Katsikis   +12 more
doaj   +1 more source

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

American journal of hematology/oncology, 2019
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
T. Munir, Jennifer R. Brown, S. O'brien, J. Barrientos, P. Barr, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, T. Kipps, C. Moreno, M. Montillo, J. Burger, J. Byrd, P. Hillmen, S. Dai, A. Szoke, J. Dean, J. Woyach   +19 more
semanticscholar   +1 more source

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Blood, 2023
Key Points • Higher effector T-cell numbers and their rejuvenated cytotoxic function accompanies favorable clinical responses to ibrutinib-rituximab.• Enhanced CD8+ T-cell lytic synapse activity during ibrutinib-rituximab therapy can be exploited using ...
D. Papazoglou, Victoria Wang, T. Shanafelt, C. Lesnick, N. Ioannou, Giulia De Rossi, S. Herter, M. Bacac, Christian Klein, M. Tallman, Neil E. Kay, A. Ramsay   +11 more
semanticscholar   +1 more source

Lymphocytosis and ibrutinib treatment of CLL

Blood, 2014
In this issue of Blood , Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.[1][1] ![
ROSSI, Davide, GAIDANO, Gianluca
openaire   +5 more sources

Ibrutinib Contributes to Atrial Arrhythmia through the Autophagic Degradation of Connexins by Inhibiting the PI3K-AKT-mTOR Signaling Pathway

Frontiers in Bioscience-Landmark
Background: Ibrutinib could increase the risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL) patients. However, the precise mechanism underlying ibrutinib-induced AF remains incompletely elucidated.
Huiyuan Qin, Bingyu Zheng, Zhiqiao Lin, Yumeng Ji, Cheng Wang, Huayuan Zhu, Chang Cui, Zidun Wang, Minglong Chen   +8 more
doaj   +1 more source

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

Case Reports in Oncological Medicine, 2016
Introduction. Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings. Case Presentation.
William Paul Skelton IV, Neeka N. Akhavan, Zachary A. Taylor, Thu-Cuc Nguyen, Hassan Hassan, Tabitha N. Townsend, Prajwol Pathak, Gaurav Trikha, Nam H. Dang, Long H. Dang, Azka Ali   +10 more
doaj   +1 more source

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Medicina, 2023
Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies.
Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu   +9 more
doaj   +1 more source

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. [PDF]

, 2016
The clinical course of chronic lymphocytic leukaemia (CLL) is heterogeneous, and treatment options vary considerably. The Connect® CLL registry is a multicentre, prospective observational cohort study that provides a real-world perspective on the ...
Farber, Charles M, Flick, E Dawn, Flinn, Ian W, Flowers, Christopher R, Grinblatt, David L, Kay, Neil E, Kipps, Thomas J, Kiselev, Pavel, Kozloff, Mark F, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P, Sullivan, Kristen, Swern, Arlene S, Weiss, Mark A   +15 more
core   +1 more source

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

New England Journal of Medicine, 2019
BACKGROUND Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL).
N. Jain, M. Keating, P. Thompson, A. Ferrajoli, J. Burger, G. Borthakur, Koichi Takahashi, Z. Estrov, N. Fowler, T. Kadia, M. Konopleva, Y. Alvarado, M. Yilmaz, Courtney D. DiNardo, P. Bose, M. Ohanian, N. Pemmaraju, E. Jabbour, K. Sasaki, R. Kanagal-Shamanna, K. Patel, J. Jorgensen, N. Garg, Xuemei Wang, K. Sondermann, Nichole D Cruz, Chongjuan Wei, A. Ayala, W. Plunkett, H. Kantarjian, V. Gandhi, W. Wierda   +31 more
semanticscholar   +1 more source